Legalization of THC Sales in Alexander City Council

Dec.13.2022

THC, derived from marijuana, can treat or prevent nausea and vomiting caused by cancer drugs. It was legalized statewide unexpectedly.

THC, which is derived from marijuana and can be used to treat or prevent nausea and vomiting caused by cancer medications, was unexpectedly legalized statewide by the State Council on July 1st.

Five companies in Alexandria Port have applied for a license to sell products containing tetrahydrocannabinol (THC), a compound that can cause marijuana to produce a state of excitement.

On Monday, December 12th, the Alexander City Council approved a submission from Ebacco after receiving additional information during a public hearing. However, approval for other applications was delayed due to incomplete submissions.

The THC licensing process is new, having only been approved by the council a few months ago.

THC, which is derived from cannabis, can be used to treat or prevent nausea and vomiting caused by cancer drugs. Surprisingly, the state legislature legalized it statewide on July 1.

This has led city leaders throughout the state to race to find answers on how to regulate the sale of THC through zoning and permits. In October, Alexandria passed a 16-page ordinance that regulates the sale and manufacture of THC-infused edibles, such as gummy bears.

This regulation mandates a license annual fee of $500 and an initial application investigation fee of $500.

Five companies have applied for licenses, including Ebacco located at 410 30th Ave. East, two locations of King Tobacco at 4617 Highway 29 South and 307 N. Nokomis St, Brothers Market at 610 McKay Ave., and Speedway gas station at 1422 Broadway.

#THC products #THC e-cigarettes

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Special Report | Anti-Vaping Campaign in the Baltics Goes Sideways

2Firsts analyzes vaping regulations across the Baltic states. Following Latvia’s flavor ban, tax revenues fell and the black market expanded, while similar measures in Estonia and Lithuania have also failed to deliver results. The region’s anti-vaping policies are now triggering market imbalance and policy reassessment.

Oct.13

ARAC to 2Firsts | FDA’s Nicotine Pouch Pilot: What Hasn’t Changed Matters Most

In a contribution to 2Firsts, U.S. regulatory consultancy ARAC analyzes the FDA’s nicotine pouch PMTA pilot, cautioning that core evidentiary standards remain unchanged. The firm warns against overinterpreting the pilot and urges companies to act now rather than wait for uncertain regulatory shifts.

Oct.21

British American Tobacco’s Irish unit says VELO pouch sales hit 29m, net revenue climbs to €33.75m

British American Tobacco’s Irish subsidiary PJ Carroll & Co Ltd reported that sales of its Velo nicotine pouches nearly quintupled in 2024 to 29 million units, driving an 11% year-on-year increase in net revenue to €33.75 million. However, amid a heavy tax burden and declining traditional cigarette volumes, the company’s pre-tax profit fell 8% to €5.69 million.

Dec.01 by 2FIRSTS.ai

ceshi1111

Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st

Oct.21